Jan 5, 2026Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer StudyEnrollment • Phase 2
Dec 17, 2025Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast CancerInterim Data • Phase 2
